Cardiff Oncology to Present at Upcoming Investor Conferences
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotech company focused on PLK1 inhibition for cancer therapies, has announced its participation in two upcoming investor conferences.
At the B. Riley Securities Precision Oncology & Radiopharma Conference on February 28, 2025, CEO Mark Erlander will participate in a panel discussion focusing on improving responses in colorectal cancer. This event will be held in New York City and is exclusively for in-person attendees.
Additionally, the company will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 5, 2025, at 11:50 AM ET. This presentation will be accessible via webcast through Cardiff Oncology's website in the 'Events' section, with a replay available after the presentation.
Cardiff Oncology (Nasdaq: CRDF), una società biotecnologica in fase clinica focalizzata sull'inibizione di PLK1 per terapie contro il cancro, ha annunciato la sua partecipazione a due prossime conferenze per investitori.
Al B. Riley Securities Precision Oncology & Radiopharma Conference del 28 febbraio 2025, il CEO Mark Erlander parteciperà a una discussione panel incentrata sul miglioramento delle risposte nel cancro colorettale. Questo evento si svolgerà a New York City ed è riservato esclusivamente ai partecipanti in presenza.
Inoltre, la società presenterà al TD Cowen 45th Annual Health Care Conference a Boston il 5 marzo 2025, alle 11:50 AM ET. Questa presentazione sarà accessibile tramite webcast attraverso il sito web di Cardiff Oncology nella sezione 'Eventi', con una registrazione disponibile dopo la presentazione.
Cardiff Oncology (Nasdaq: CRDF), una empresa biotecnológica en etapa clínica centrada en la inhibición de PLK1 para terapias contra el cáncer, ha anunciado su participación en dos próximas conferencias para inversores.
En la B. Riley Securities Precision Oncology & Radiopharma Conference el 28 de febrero de 2025, el CEO Mark Erlander participará en una discusión en panel centrada en mejorar las respuestas en el cáncer colorrectal. Este evento se llevará a cabo en la ciudad de Nueva York y es exclusivamente para asistentes presenciales.
Además, la empresa presentará en la TD Cowen 45th Annual Health Care Conference en Boston el 5 de marzo de 2025, a las 11:50 AM ET. Esta presentación será accesible a través de un webcast en el sitio web de Cardiff Oncology en la sección 'Eventos', con una repetición disponible después de la presentación.
카디프 온콜로지 (Nasdaq: CRDF), 암 치료를 위한 PLK1 억제에 중점을 둔 임상 단계의 생명공학 회사가 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다.
B. 라이리 증권 정밀 종양학 및 방사선 제약 회의에서 2025년 2월 28일, CEO 마크 얼랜더가 대장암에 대한 반응 개선을 주제로 패널 토론에 참여할 예정입니다. 이 행사는 뉴욕 시에서 열리며, 현장 참석자만을 위한 행사입니다.
또한, 회사는 2025년 3월 5일 오전 11시 50분 ET에 보스턴에서 열리는 TD 코웬 제45회 연례 건강 관리 회의에서 발표할 예정입니다. 이 발표는 카디프 온콜로지 웹사이트의 '이벤트' 섹션을 통해 웹캐스트로 접근할 수 있으며, 발표 후 재생이 가능합니다.
Cardiff Oncology (Nasdaq: CRDF), une entreprise de biotechnologie en phase clinique axée sur l'inhibition de PLK1 pour les thérapies contre le cancer, a annoncé sa participation à deux prochaines conférences pour investisseurs.
Lors de la B. Riley Securities Precision Oncology & Radiopharma Conference le 28 février 2025, le PDG Mark Erlander participera à une discussion en panel axée sur l'amélioration des réponses dans le cancer colorectal. Cet événement se déroulera à New York et est exclusivement réservé aux participants en personne.
De plus, l'entreprise présentera à la TD Cowen 45th Annual Health Care Conference à Boston le 5 mars 2025 à 11h50 ET. Cette présentation sera accessible par webcast via le site web de Cardiff Oncology dans la section 'Événements', avec une rediffusion disponible après la présentation.
Cardiff Oncology (Nasdaq: CRDF), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die PLK1-Hemmung für Krebstherapien konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt.
Auf der B. Riley Securities Precision Oncology & Radiopharma Conference am 28. Februar 2025 wird CEO Mark Erlander an einer Podiumsdiskussion teilnehmen, die sich auf die Verbesserung der Reaktionen bei Kolorektalkrebs konzentriert. Diese Veranstaltung findet in New York City statt und ist ausschließlich für persönliche Teilnehmer.
Darüber hinaus wird das Unternehmen am TD Cowen 45th Annual Health Care Conference in Boston am 5. März 2025 um 11:50 Uhr ET präsentieren. Diese Präsentation wird über einen Webcast auf der Website von Cardiff Oncology im Abschnitt 'Veranstaltungen' zugänglich sein, mit einer Wiederholung, die nach der Präsentation verfügbar ist.
- None.
- None.
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences.
Details of the presentations can be found below.
B. Riley Securities Precision Oncology & Radiopharma Conference
Presenter: Mark Erlander, CEO
Format: Panel discussion on “What It Takes to Move the Needle in Improving Responses in Colorectal Cancer”’
Date: 02/28/2025
Location: New York City, NY
This event is for in-person participants only. Contact B. Riley for information on attending the conference.
TD Cowen 45th Annual Health Care Conference
Presenter: Mark Erlander, CEO
Format: Company presentation
Date: 03/5/2025
Time: 11:50 AM ET
Location: Boston, MA
Interested parties can register for and access the live webcast for TD Cowen by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com
Media Contact:
Michael Lauer
Taft Communications
732-233-4881
michael@taftcommunications.com
FAQ
When is Cardiff Oncology (CRDF) presenting at the TD Cowen Healthcare Conference?
How can investors access Cardiff Oncology's TD Cowen conference presentation?
What is the topic of Cardiff Oncology's panel discussion at the B. Riley Securities conference?
Which investor conferences will Cardiff Oncology (CRDF) attend in early 2025?
Is the B. Riley Securities conference presentation available virtually for CRDF investors?
